Problems with exocrine gland function in patients with Sjögren’s syndrome as well as the low TRPV4 expression levels in patients with AIGA suggest that TRPV4 could be a key molecule involved in these diseases and that novel treatment strategies could target TRPV4 and/or ANO1. Here, ANO1 is linked to Sjogren syndrome.